



Eurofins joins the SBF 120 index

June 19, 2009

Eurofins is pleased to announce its admission to the SBF 120 index, following the decision made by the Index Scientific Committee at NYSE Euronext Paris on 28 May. This decision will take effect as of today, Friday 19 June 2009, after the market closes.

The SBF 120 is an index of the Paris Stock Exchange which groups the 120 largest companies by market capitalization and by trading volumes on NYSE Euronext Paris. It is widely used as a benchmark for the evaluation of funds invested in French shares.

Commenting on this decision, Gilles Martin, CEO of Eurofins Group, said: "We are very proud of the NYSE Euronext Index Committee's decision. Eurofins' admission to the SBF 120 index will help to raise further our profile among investors and enhance the liquidity of our shares to the benefit of our shareholders. This reflects well on the hard work of our 8,000 employees to raise standards in food safety for the benefit of all society".

For further information please contact:

Investor Relations
Phone: +32-2-769 7383
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.

The Eurofins Group is the world leader in food testing and one of the global market leaders in pharmaceuticals and environmental testing. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910 251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.